DekaBank Deutsche Girozentrale Has $1.12 Million Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

DekaBank Deutsche Girozentrale grew its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 7.9% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 10,551 shares of the medical equipment provider’s stock after buying an additional 768 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in Lantheus were worth $1,121,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in LNTH. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Lantheus in the third quarter valued at approximately $849,000. Assenagon Asset Management S.A. bought a new stake in shares of Lantheus during the third quarter worth $1,863,000. Moody Aldrich Partners LLC acquired a new position in shares of Lantheus during the third quarter valued at $4,211,000. Riverwater Partners LLC acquired a new position in shares of Lantheus during the third quarter valued at $580,000. Finally, International Assets Investment Management LLC increased its position in Lantheus by 4,324.9% in the third quarter. International Assets Investment Management LLC now owns 66,948 shares of the medical equipment provider’s stock worth $7,348,000 after purchasing an additional 65,435 shares during the period. 99.06% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Gerard Ber sold 15,500 shares of the business’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the sale, the director now directly owns 21,221 shares of the company’s stock, valued at approximately $2,047,402.08. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, President Paul Blanchfield sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $96.39, for a total transaction of $192,780.00. Following the completion of the transaction, the president now directly owns 98,980 shares of the company’s stock, valued at $9,540,682.20. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gerard Ber sold 15,500 shares of the business’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the completion of the sale, the director now directly owns 21,221 shares in the company, valued at approximately $2,047,402.08. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.50% of the company’s stock.

Lantheus Stock Down 1.7 %

NASDAQ:LNTH opened at $107.98 on Friday. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $126.89. The stock has a 50-day moving average price of $108.13 and a two-hundred day moving average price of $94.40. The stock has a market cap of $7.50 billion, a price-to-earnings ratio of 17.70 and a beta of 0.51. The company has a current ratio of 4.68, a quick ratio of 4.41 and a debt-to-equity ratio of 0.55.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The business had revenue of $394.10 million during the quarter, compared to analyst estimates of $382.12 million. During the same quarter in the prior year, the firm posted $1.40 earnings per share. Lantheus’s revenue for the quarter was up 22.5% compared to the same quarter last year. As a group, equities analysts expect that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on LNTH. Leerink Partners upped their target price on shares of Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a research report on Thursday, July 11th. JMP Securities cut their price objective on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a report on Thursday, August 1st. Truist Financial lowered their target price on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a report on Thursday, August 1st. Redburn Atlantic assumed coverage on Lantheus in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price target on the stock. Finally, B. Riley lifted their price objective on Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, Lantheus has a consensus rating of “Moderate Buy” and a consensus price target of $126.00.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.